Published in Gene Therapy Weekly, June 10th, 2004
Existing procedures for prediction of recurrence of prostate cancer, including blood tests such as the prostate specific antigen test and other standard pathological examinations that have been used for decades, have limited prognostic capability. According to the company, AntiCancer's clinically relevant MetaMouse...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.